• The Medtronic of aortic repair.
• Edwards Lifesciences for the entire aorta.

• Perceval Sutureless Heart Valve: A device for aortic valve replacement that eliminates the need for sutures, simplifying the surgical procedure.
• On-X Mechanical Heart Valves: Prosthetic heart valves designed for long-term replacement of the aortic or mitral valve.
• E-vita OPEN NEO: A hybrid stent graft system used for the simultaneous treatment of the ascending aorta and aortic arch.
• BioGlue Surgical Adhesive: A surgical sealant used to reinforce suture lines and achieve hemostasis in cardiovascular and vascular procedures.
• ENDOCARE and NEXUS Endovascular Stent Grafts: Devices designed for the minimally invasive repair of thoracic aortic aneurysms and dissections.

J. Patrick Mackin, Chairman, President, and Chief Executive Officer

Mr. Mackin joined Artivion in September 2014 and was appointed Chairman in April 2015. He brings over 30 years of experience in the medical device industry. Prior to Artivion, he served as President of Cardiac Rhythm Disease Management, the largest operating division of Medtronic, Inc., and held senior leadership positions at Genzyme.

Lance A. Berry, Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer

Mr. Berry was appointed as Artivion's Chief Financial Officer on December 4, 2023. He previously served as Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V. from January 2019 until its acquisition by Stryker in November 2020. Before that, he was Senior Vice President, Chief Financial Officer for Wright from 2009 to 2018, where he successfully spearheaded its merger with Tornier N.V. His expertise includes strategy, M&A, and financing.

John E. Davis, Chief Commercial Officer

Mr. Davis was appointed Chief Commercial Officer in February 2024 and has over 25 years of experience in sales, marketing, and executive leadership. Prior to Artivion, he was Executive Vice President of Sales and Marketing at CorMatrix and served as a Vice President of Sales in the Cardiac Rhythm Management Devices business at St. Jude Medical.

Jean F. Holloway, Esq., Senior Vice President, General Counsel, Chief Compliance Officer and Secretary

Ms. Holloway holds the titles of Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary at Artivion.

Marshall S. Stanton, M.D., Senior Vice President, Clinical Research, and Chief Medical Officer

Dr. Stanton was appointed Senior Vice President, Clinical Research, and Chief Medical Officer in March 2021. He has over 20 years of experience in the medical device industry and more than 30 years in advancing healthcare. Before joining Artivion, he held various senior management positions at Medtronic, Inc., including Senior Vice President and President of the Pain Therapies Business Unit. Dr. Stanton is scheduled to retire effective March 31, 2026.

Key Risks to Artivion (AORT) Business

1. Financial Leverage and Debt

2. Regulatory Approvals and Market Adoption of New Products

3. Cybersecurity Incidents and Supply Chain Disruptions

• Ascyrus Medical Dissection Stent (AMDS): For the treatment of acute DeBakey Type I aortic dissections, the addressable market in the U.S. is an estimated $150 million annually.
• On-X Mechanical Heart Valves: Artivion is pursuing a new $100 million annual market opportunity in the U.S. for its On-X heart valve, driven by new clinical data. Globally, the prosthetic heart valve market was valued at $9.64 billion in 2024 and is projected to reach $20.69 billion by 2033. Aortic procedures constituted 56.53% of this market in 2024. North America held the largest share of the global prosthetic heart valve market in 2024, at 48.5%.

Artivion (AORT) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and product performances:

1. Continued Adoption and Expansion of AMDS: The successful launch and growing adoption of the AMDS (Aortic Modular Stent Graft) in the U.S. is a significant driver. Stent graft revenues, largely fueled by AMDS, increased by 31% on a constant currency basis in Q3 2025. The company also anticipates sequential growth in AMDS sales throughout 2025. A new reimbursement code (MSDRG DRG-209), effective October 1, 2025, is expected to provide a tailwind by increasing reimbursement for advanced aortic arch procedures, thereby reducing cost constraints for healthcare providers and further supporting AMDS adoption. Artivion plans to submit PMA applications for AMDS with a target for PMA approval in mid-2026.
2. Global Market Share Gains and Growth of On-X Heart Valve: The On-X heart valve business has demonstrated exceptional growth, with a 23% increase in revenue in Q3 2025 and 24% year-over-year growth in Q2 2025 on a constant currency basis. This growth is attributed to its unique clinical profile, including its low INR indication from the FDA, and continued market share gains globally, particularly for patients under 65. Artivion is actively educating healthcare providers on clinical data demonstrating the mortality benefit of On-X in certain patient populations.
3. Launch and Commercialization of Nexus: Artivion has a robust product pipeline, with Nexus identified as a promising product expected to unlock significant market opportunities. The company is optimistic about Nexus's approval in the second half of 2026 and has made financial arrangements, including a $150 million delayed draw term loan, to acquire Endospan following FDA approval, which would grant access to an estimated $150 million annual U.S. market opportunity. One-year clinical data from the Nexus trial is expected to be presented in January 2026.
4. Geographic Expansion, particularly in North America and Asia Pacific: Artivion has shown strong regional revenue growth, with North America increasing by 19% and Asia Pacific by 18% in Q3 2025. This indicates successful market penetration and presents opportunities for continued growth in these regions through increased sales and adoption of their product portfolio.

Share Issuance

• In May 2025, Artivion completed agreements to exchange approximately $99.54 million in principal amount of its 4.250% Convertible Senior Notes due 2025 for 4,334,347 shares of common stock.
• In August 2025, Artivion registered 3,570,000 additional shares of common stock for issuance under its 2020 Equity and Cash Incentive Plan, following Board and stockholder approval in March and May 2025, respectively.
• The number of issued shares increased by 758,000 during Q1 2025, from 43.432 million as of December 31, 2024, to 44.190 million as of March 31, 2025.

Outbound Investments

• Artivion's capital allocation strategy in September 2025 was focused on the planned acquisition of Endospan.

Capital Expenditures

• Capital expenditures for Q2 2025 were $3.287 million, and $6.925 million year-to-date Q2 2025.
• Artivion's capital expenditures average $2 million to $3.6 million per quarter, primarily supporting asset base maintenance.
• Ongoing research and development (R&D) investments, approximately 7% to 8% of revenue, are crucial for maintaining competitive advantage.